The weight loss provided by CagriSema in Phase 3 trials beats current leading products for ... could further erode Novo's lead. FILE PHOTO: A view shows the logo of Novo Nordisk at the company's ...

The maker of weight loss drugs Ozempic and Wegovy broke rules around the advertising and marketing of its medication to healthcare workers over three years, the medicines watchdog has found.

Under the terms of the agreement, Novo Nordisk also receives exclusive rights to expand any resulting metabolic disease products into other therapeutic ... Ascendis, Ascendis Pharma, the Ascendis ...